- 2600 Stemmons Freeway,
- Suite 176
- Dallas, TX 75207-2107
- Tel: (214) 905-5100
- Fax: (214) 905-5101
Some of Access Pharmaceuticals product candidates need to complete testing in human clinical trials to provide a basis for the U.S. Food and Drug Administration (FDA) or other health regulatory agency to review and potentially approve them for use in humans. The outcome of each stage of these clinical trials is necessarily uncertain as to the actual and perceived safety and efficacy of each potential treatment and the FDA would have to review and approve a licensing application before a product candidate could be marketed for any indication. Success in preclinical and early clinical trials does not ensure that later-stage or larger-scale clinical trials would be successful. Nor can there be any assurance that a product would ultimately prove to be safe and effective in humans. Please see the Note Regarding Forward-Looking Statements in this Web site for additional information regarding these and other risks and uncertainties.
Access is a company with product candidates in various stages of ongoing development. As a result, a substantial number of statements contained in this Web site, including without limitation statements containing words such as "believes", "anticipates", "expects", "predicts", "plans", "intends", "could", "would", and "will", and words of similar import, may constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Access, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For example, risks and uncertainties that exist in the companys operations and business environment include, without limitation, the companys early stage of product development, its dependence upon proprietary technology, its current competition, its history of operating losses and accumulated deficits, its reliance on collaborative relationships, as well as uncertainties related to clinical trials including the actual or perceived safety or efficacy of a product candidate and the ability to obtain the appropriate regulatory approvals, patent protection and market acceptance, as well as other risks and uncertainties detailed from time to time in the companys filings with the Securities and Exchange Commission (SEC). Please see the companys most recent periodic reports on Form 10-K and Form 10-Q as well as the companys reports on Form 8-K and other reports filed from time to time with the SEC for information about risks and uncertainties which may affect us. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.
In general, you can choose to visit Access Pharmaceuticals on the Web without identifying yourself or revealing any personal information. If you contact us and choose to provide personally identifiable information, we plan to utilize it to respond to requests you may make of us and to otherwise support your relationship with Access. We may refer to your information to better understand your needs and how we can improve this Web site. We do not intend to collect or maintain personally identifiable information for resale purposes. Any and all uses are intended to comply with applicable laws.
From time to time, this Web site may be configured to track the total number of visitors to this site and the number of visitors to each page, and to collect domain information, as part of our analysis of the use of this site. Access plans to use this information to improve this Web site. This information is collected automatically and requires no action on your part.